Novo Nordisk A/S Class B (0QIU)

633.35
-9.60(-1.49%)
  • Volume:
    279,407
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    633.35 - 633.35

0QIU Overview

Prev. Close
642.95
Day's Range
633.35-633.35
Revenue
-
Open
646.3
52 wk Range
409.96-682.1
EPS
-
Volume
279,407
Market Cap
1.47T
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
236,460
P/E Ratio
33.49
Beta
-
1-Year Change
43.55%
Shares Outstanding
2,289,895,562
Next Earnings Date
Nov 03, 2021
What is your sentiment on Novo Nordisk L?
or
Market is currently closed. Voting is open during market hours.

Novo Nordisk L News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellNeutralStrong Buy
Technical IndicatorsStrong SellStrong SellStrong SellBuyStrong Buy
SummaryStrong SellStrong SellStrong SellNeutralStrong Buy

Novo Nordisk L Company Profile

Novo Nordisk L Company Profile

Employees
45971
Market
Denmark

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Read More
  • Results from clinical study just published in New England Journal of Medicine: Impressive new weight loss results for Semaglutide at only 2.4 mg once a week. Drug mimics the gut hormone glucagon-like peptide-1 (GLP-1) that is secreted by your gut after eating.
    1
    • Now is the time to buy - novo is very seasonal stock goes up the most in jan/feb.
      0
      • bullish??
        0
        • No. Funds are selling. Time to wait to go long...
          0
      • Perfect opportunity to make short,,
        1
        • can you explain why please?
          0
        • No explaning? 🤷
          0
        • because he has no explanation. Novo nordisk is a soli long-term stock. I know a lot about opioid treatments, and methadon is changing to lipo-methadon, wich has really only one competitor on the global field. That competitor is Camurus AB with their product buvidol. I tecommend to all investors to buy and HOLD for these two companies, because there is no other options for a opioid-replacement-care, except Suboxone, and that is going to be replaced Lipo-methadon or Buvidol, at least here in Finland. Suboxone is manufactured for Indivor Inc, by Aquestive Therapeutics, if someone wants to do a little research.
          0
      • Bullish sentiment.
        0
        • Why is going so low???
          0
          • Anyone got a view on how much the Trump/US plans to reduce medical prices will affect the share price?
            0
            • Extremely bullish double bottom pattern and fibbonacci retracement with convergence of relative strenght index upwards
              0
              • Comenté hace unos meses que es un valor muy sólido, que lo veríamos pronto en 200 $ (que con el split son 40 $), pues bien, ha superado mis expectativas y está en 45 $.... me aventuro a pronosticar que cerrará el año en torno a los 50 $. Saludos
                0
                • Comenté hace unos meses que es un valor muy sólido, que lo veríamos pronto en 200 $ (que con el split son 40 $), pues bien, ha superado mis expectativas y está en 45 $.... me aventuro a pronosticar que cerrará el año en torno a los 50 $. Saludos
                  0
                  Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                  Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.